Research and Markets: US In Vitro Diagnostics Market Expected to Grow at a CAGR of 5.45% over the period 2014-2019, New Report Says

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/g27cgm/ivd_market_in_the) has announced the addition of the "IVD Market in the US 2015-2019" report to their offering.

Disease management and individualized treatment can be enabled by diagnostic tests, which can provide real-time or rapid results. For instance, glycated hemoglobin and blood glucose monitoring tests for diabetes, cholesterol monitoring in lipid-lowering therapy, and blood level monitoring of antiretroviral drugs in HIV strains allow clinicians to obtain diagnostic information and reduce the likelihood of adverse events. These treatments can also be managed by real-time, customized approaches. Personalizing these treatments will enable better channeling of diagnostic information of the patient, and thereby communicate results directly to clinicians.

According to the report, the Healthcare Reform Act of 2010 aimed to increase accessibility and provide quality healthcare at affordable costs to all citizens. Since its initiation, there has been an increase in the number of citizens covered by insurance. According to the Congressional Budget Office, by 2015, almost 19 million US citizens will be covered by insurance as a result of PPACA. In addition, it introduced preventive services for women such as screening for cervical cancer and mammograms, which will be covered by health plans. The full-time employees of large companies also benefited because they were initially denied health insurance by their employers. These factors will give an impetus to the growth of the market.

Further, the report states that regulatory and reimbursement issues hinder the sales of IVD components, thereby hampering market growth.

Key Topics Covered

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Market Research Methodology
  5. Introduction
  6. US Healthcare Reform
  7. Reimbursement and Coverage: An Overview
  8. Market Landscape
  9. Market Segmentation by Application
  10. Market Segmentation by Technique
  11. Market Segmentation by Component
  12. Market Segmentation by End-users
  13. Buying Criteria
  14. Market Growth Drivers
  15. Drivers and their Impact
  16. Market Challenges
  17. Impact of Drivers and Challenges
  18. Market Trends
  19. Trends and their Impact
  20. Vendor Landscape
  21. Key Vendor Analysis

Companies Mentioned

  • A. Menarini Diagnostics
  • ARKRAY
  • Abbott Laboratories
  • Affymetrix
  • Agilent Technologies
  • Alere
  • Axis-Shield
  • bioMérieux
  • Bio-Rad Laboratories
  • Bruker BioSciences
  • Cepheid
  • Dako
  • Danaher
  • DiaSorin
  • ELITech
  • Eiken Chemical
  • Fujirebio Diagnostics
  • GE Healthcare
  • Grifols
  • Horiba
  • Illumina
  • Instrumentation Laboratory
  • Johnson & Johnson
  • Luminex
  • Magellan Biosciences
  • Nanosphere
  • Nova Biomedical
  • Nova Century Scientific
  • PerkinElmer
  • Phadia
  • QIAGEN
  • Quest Diagnostics
  • Quidel
  • Randox Laboratories
  • Roche Diagnostics
  • Siemens Healthcare
  • Sysmex Hematology
  • Tosoh
  • Trinity Biotech
  • Werfen Life

For more information visit http://www.researchandmarkets.com/research/g27cgm/ivd_market_in_the.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: In Vitro Diagnostics

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: In Vitro Diagnostics